Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PRO-229
- Development stage
- Phase 1
- Lead developer
- Laboratorios Sophia
- Modality
- Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Implantable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Non-biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Ophthalmic
01
Overview
PRO-229 is an investigational **fixed-dose ophthalmic solution** developed by Laboratorios Sophia containing **dexpanthenol 2%** and **sodium hyaluronate 0.15%**. The formulation is intended to lubricate and support hydration of the ocular surface, with dexpanthenol supporting epithelial recovery and sodium hyaluronate providing viscoelastic tear-film supplementation. It was evaluated in a completed Phase 1 safety and tolerability study in clinically healthy adults, with dry eye disease and ocular surface disease listed as study conditions. ([ctv.veeva.com](https://ctv.veeva.com/study/clinical-study-to-evaluate-the-safety-and-tolerability-of-pro-229-ophthalmic-solution-compared-to-la))
- Other names
- PRO 229PRO229PRO-229
Beyond the preview
Go deeper on PRO-229.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PRO-229.